Can You Take AOD-9604 With Retatrutide? What the Research Says About Combining Them

Retatrutide and AOD-9604 have both attracted attention for fat loss, but they are very different compounds. Retatrutide is an investigational triple receptor agonist with substantial clinical trial data for obesity. AOD-9604 is a modified fragment of human growth hormone that was developed to influence fat metabolism without reproducing all of growth hormone’s systemic effects.

That difference creates an appealing theory: could targeting separate metabolic pathways produce complementary fat-loss effects? The biological rationale is interesting, but the clinical evidence is not yet strong enough to establish the safety or effectiveness of an AOD-9604 and retatrutide combination. There are also important regulatory and safety considerations because neither compound is currently FDA-approved for routine clinical use.

This article explains how retatrutide and AOD-9604 work, what human research actually shows, why glucose regulation and other metabolic markers matter, and what to discuss with a licensed prescribing clinician before considering any investigational peptide strategy.

Key Takeaways

• Retatrutide is an investigational GLP-1, GIP, and glucagon receptor agonist that has produced substantial weight loss in clinical obesity trials, but it is not FDA-approved as of August 2026.
• AOD-9604 is a modified fragment of human growth hormone studied for effects on fat metabolism, but human obesity trials have not established compelling weight-loss efficacy and it is not FDA-approved.
• There is currently insufficient clinical evidence to establish that combining AOD-9604 with retatrutide produces greater fat loss or is safe.
• Glucose, hemoglobin A1C, fasting insulin, medication history, body composition, nutrition, and other clinical factors can provide useful context when evaluating metabolic health.
• There is no evidence-based, FDA-approved dosing schedule for an AOD-9604 and retatrutide stack. Specific dosing or cycling should not be extrapolated from informal peptide protocols.
• Anyone considering investigational compounds should involve a licensed clinician who can assess risks, explain regulatory status, and monitor appropriate laboratory and clinical markers.

What Is Retatrutide?

Retatrutide is an investigational peptide developed by Eli Lilly for obesity and related metabolic conditions. It simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

This triple-agonist design separates retatrutide from semaglutide, which targets GLP-1 receptors, and tirzepatide, which targets GLP-1 and GIP receptors. The glucagon receptor component is particularly interesting because glucagon signaling can affect hepatic metabolism and energy expenditure, although its physiology is more complex than simply “burning more calories.”

How Retatrutide May Support Weight Loss

Retatrutide’s effects likely arise from several interacting mechanisms. GLP-1 and GIP signaling influence appetite, food intake, glucose-dependent insulin secretion, and metabolic regulation. Glucagon receptor activation can influence liver glucose production, lipid metabolism, and energy expenditure.

In a Phase 2 obesity trial published in The New England Journal of Medicine in 2023, participants receiving the highest studied dose achieved a mean weight reduction of approximately 24% at 48 weeks. Later Phase 3 research has continued to evaluate retatrutide across obesity and obesity-related conditions.

These results make retatrutide one of the more closely watched investigational obesity therapies. However, impressive clinical trial results do not make an unapproved drug appropriate for unsupervised use. Its benefits, adverse effects, contraindications, and longer-term safety must be considered in the context of regulated clinical evidence.

What Is AOD-9604?

AOD-9604 is a modified peptide based on amino acids 176-191 near the C-terminal region of human growth hormone. It was developed in an attempt to reproduce certain lipid-metabolism effects associated with growth hormone while avoiding some of the hormone’s broader growth-promoting activity.

Preclinical work suggested effects on lipolysis and fat oxidation. Lipolysis is the process through which stored triglycerides are broken down into fatty acids and glycerol so they can become available for metabolism.

Does AOD-9604 Increase IGF-1?

Growth hormone can stimulate production of insulin-like growth factor 1, or IGF-1, which mediates many of its growth and tissue effects. AOD-9604 was designed specifically to avoid acting like full-length growth hormone, and available research has not demonstrated the same IGF-1-stimulating profile.

This distinction is important. AOD-9604 should not be treated as interchangeable with growth hormone or growth hormone secretagogues such as CJC-1295, ipamorelin, or tesamorelin. Those compounds have different mechanisms, evidence bases, and regulatory statuses.

What Do Human Studies Show About AOD-9604?

The human evidence is much less compelling than the mechanistic theory. AOD-9604 underwent clinical development for obesity, but the program did not ultimately demonstrate sufficient weight-loss efficacy to establish it as an approved obesity treatment. It remains unapproved by the FDA.

That makes an important distinction between biological plausibility and proven clinical benefit. A compound can alter fat metabolism in laboratory or animal research without producing meaningful, reproducible weight loss in humans.

Can You Combine AOD-9604 With Retatrutide?

There is not enough controlled human evidence to say that an AOD-9604 and retatrutide combination is safe or more effective than retatrutide alone. The compounds operate through different pathways, which creates a theoretical rationale for complementary effects, but a plausible mechanism is not the same as clinical evidence of synergy.

Retatrutide already influences appetite, glucose metabolism, and energy balance through three receptor systems. AOD-9604 has been investigated primarily for lipid metabolism. Researchers would need properly designed combination studies to determine whether adding AOD-9604 produces meaningful additional fat loss, changes adverse-event rates, or interacts with retatrutide in unexpected ways.

This is especially relevant because combination therapy can introduce uncertainty. Two compounds do not need to bind the same receptor to produce overlapping physiological effects or change a patient’s overall risk profile.

Why Metabolic Health and Blood Testing Matter

Weight loss is only one measure of metabolic health. Baseline and follow-up testing can help a clinician understand how an individual is responding to nutrition, weight loss, existing medications, and any medically appropriate therapy.

Blood Glucose and Hemoglobin A1C

Fasting glucose provides a snapshot of blood glucose at one point in time, while hemoglobin A1C estimates average glycemic exposure over roughly two to three months. Both can help identify normal glucose regulation, prediabetes, diabetes, or treatment-related changes.

Retatrutide directly affects pathways involved in glucose homeostasis. Its glucagon activity also makes simplistic predictions about blood sugar inappropriate. Clinical trials, rather than receptor theory alone, are necessary to characterize the net metabolic effect.

Fasting Insulin and C-Peptide

Fasting insulin can add context about insulin dynamics, although it does not have a single universally accepted optimization target for every individual. C-peptide reflects endogenous insulin production because it is released when the pancreas produces insulin.

These markers can be useful in selected clinical situations, but interpreting them requires context. A laboratory value should not be treated as a standalone green light for a peptide protocol. Medical history, medications, kidney and liver function, symptoms, body composition, and established diagnostic criteria also matter.

IGF-1

IGF-1 is particularly relevant when assessing therapies that directly or indirectly affect the growth hormone axis. It can help clinicians evaluate growth hormone physiology, but interpretation is age-dependent and laboratory reference ranges vary.

For AOD-9604 specifically, the rationale behind its design was to separate potential lipolytic activity from the classic IGF-1 effects of full-length growth hormone. Monitoring strategies therefore should be based on the actual compound, patient, and clinical question rather than assuming every peptide associated with growth hormone biology behaves identically.

Potential Risks and Limitations of an AOD-9604 and Retatrutide Stack

The biggest limitation is straightforward: direct combination evidence is lacking. Without controlled trials, clinicians do not have reliable estimates for additional efficacy, optimal dosing, drug interactions, or adverse-event frequency.

Retatrutide’s clinical studies have reported gastrointestinal adverse effects, including nausea, diarrhea, vomiting, and constipation, similar to other incretin-based therapies. Individual risk also depends on medical history and concomitant medications.

AOD-9604 presents a different problem. Its evidence base is comparatively limited and it has not demonstrated sufficient efficacy to become an FDA-approved obesity treatment. Product quality is another concern when unapproved peptides are obtained from sellers marketing materials as “research use only” or “not for human consumption.” Such products should not be self-administered.

Regulatory status also deserves precision. FDA approval, lawful compounding, and products sold online for laboratory research are separate issues. The legal availability of compounded drugs depends on federal and state requirements and can change. A licensed clinician and appropriately regulated pharmacy are necessary resources for determining what is legally and medically appropriate at a given time.

Is There a Recommended Dosing Schedule?

No validated dosing protocol has been established for combining AOD-9604 with retatrutide. Although anecdotal peptide protocols sometimes recommend separating injection days or cycling compounds five days on and two days off, these practices should not be presented as proven safety measures. There is insufficient evidence that timing the compounds on different days prevents meaningful interactions or complications.

Retatrutide dosing in clinical research follows trial-specific escalation protocols designed and monitored by investigators. That does not create an appropriate do-it-yourself schedule. Likewise, there is no FDA-approved AOD-9604 dose for obesity or fat loss.

For longevity and performance optimization, more treatment is not automatically better. The goal should be to identify the minimum intervention needed to improve meaningful outcomes while protecting lean mass, nutrition status, metabolic function, and overall health.

Fat Loss Is More Than a Number on the Scale

Rapid weight reduction can include both fat mass and lean tissue. Anyone pursuing substantial weight loss should therefore pay attention to resistance training, adequate protein and micronutrient intake, sleep, recovery, and body composition.

Advanced diagnostics can help make this process more objective. Depending on individual needs, clinicians may consider metabolic labs, cardiovascular risk markers, liver and kidney function, thyroid assessment, and body-composition testing. The appropriate panel depends on medical history and should not be based solely on a desire to use a particular peptide.

This data-first approach is useful beyond peptide therapy. It can identify insulin resistance, dyslipidemia, nutrient issues, loss of muscle mass, or other barriers that deserve attention regardless of whether an investigational compound is considered.

Frequently Asked Questions

Can you take AOD-9604 and retatrutide at the same time?

There are insufficient controlled human data to establish the safety or added effectiveness of combining them. Retatrutide is still investigational, and AOD-9604 is not FDA-approved for obesity or another indication.

Does AOD-9604 make retatrutide work better?

That has not been demonstrated in clinical trials. Their different mechanisms create a theoretical argument for complementary fat-loss effects, but there is currently no reliable evidence that AOD-9604 increases weight or fat loss achieved with retatrutide.

Does AOD-9604 raise IGF-1?

AOD-9604 was developed to capture selected metabolic effects of growth hormone without its full growth-promoting activity, and available evidence has not shown the same IGF-1 response expected from growth hormone. Evidence on long-term use remains limited.

Is retatrutide FDA-approved?

No. As of August 2026, retatrutide remains an investigational drug in late-stage clinical development and is not FDA-approved for obesity or any other indication.

Is AOD-9604 FDA-approved for weight loss?

No. AOD-9604 is not FDA-approved for weight loss. Earlier clinical development did not establish sufficient obesity-treatment efficacy to lead to approval.

Which labs should be considered before a metabolic weight-loss strategy?

A clinician may consider fasting glucose, hemoglobin A1C, a lipid panel, liver and kidney markers, and other tests based on individual history. Fasting insulin, C-peptide, IGF-1, thyroid markers, and body-composition measurements may provide additional context in selected cases.

Summary

AOD-9604 and retatrutide target distinctly different aspects of metabolism. Retatrutide has produced substantial weight loss in clinical trials through combined GLP-1, GIP, and glucagon receptor agonism. AOD-9604 was developed from a fragment of growth hormone and has shown interesting metabolic activity in preclinical research, but its human weight-loss efficacy remains unproven.

The theory behind combining them is easy to understand, but there is currently insufficient clinical evidence to establish safety, synergy, or an appropriate dosing strategy. Decisions about metabolic treatment are better built around validated diagnostics, medical history, body composition, and established therapies than around peptide stacking alone.

The Next Step in Your Longevity Journey

If fat loss is part of a broader longevity goal, start by establishing measurable baseline data. Blood glucose, A1C, lipids, liver and kidney function, and body composition can help reveal whether the priority should be improving insulin sensitivity, preserving muscle, reducing visceral fat, addressing cardiovascular risk, or investigating another metabolic issue.

Advanced blood testing and diagnostics can then guide a personalized longevity strategy. When peptide protocols or investigational compounds enter the conversation, a licensed prescribing clinician should review the evidence, regulatory status, potential contraindications, current medications, and monitoring plan before any decision is made.

The objective is not simply to stack more pathways. Sustainable health optimization combines appropriate medical care with strength training, nutrition, sleep, recovery, and measurable metabolic outcomes. Readers who want to learn more about how lifestyle and peptide science intersect can download the free Peptide Blueprint or explore referenced educational research in the Ageless Future learning library.

Medical disclaimer: This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Retatrutide and AOD-9604 are not FDA-approved for the uses discussed here. Do not start, stop, combine, or change any medication, peptide, or supplement based on this article. Discuss treatment decisions with a qualified licensed clinician.

Related reading

• Does Retatrutide Increase Metabolism? The Truth About Fat Loss, Energy, and Metabolic Adaptation
• Why Retatrutide Outshines Tirzepatide: An In-Depth Comparison
• Is Tirzepatide Safe for Kidneys? What the SURPASS Trials Reveal About Kidney Health

Explore further: Stubborn Weight Protocol · Longevity Blood Panel · Schedule an intro call.